Methods of administering solriamfetol to lactating women
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
1. A method of reducing exposure to solriamfetol in an infant fed breast milk obtained from a human subject treated with solriamfetol comprising:
orally administering the solriamfetol to the subject at a once-daily dose of about 150 mg; and
feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject,
wherein the daily infant dose of solriamfetol is reduced to about 0.3 mg or lower.
2. The method of claim 1 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol exposure.
3. The method of claim 1 , wherein the subject is from 1 day to 24 months postpartum.
4. The method of claim 3 , wherein the subject is from 10 days to 12 months postpartum.
5. The method of claim 1 , wherein the subject is being treated with solriamfetol for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, attention deficit/hyperactivity disorder, depression, cognitive impairment, or binge eating disorder.
6. A method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a human subject treated with solriamfetol comprising:
administering solriamfetol orally at a once-daily dose of about 150 to the subject; and
feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject,
wherein the daily infant dose of solriamfetol is reduced to about 0.3 mg or lower.
7. The method of claim 6 , wherein the adverse events are one or more of agitation, insomnia, anorexia, or reduced weight gain.
8. The method of claim 6 , wherein the subject is being treated with solriamfetol for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, attention deficit/hyperactivity disorder, depression, cognitive impairment, or binge eating disorder.
9. The method of claim 6 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol exposure.
10. The method of claim 6 , wherein the subject is from 1 day to 24 months postpartum.
11. The method of claim 10 , wherein the subject is from 10 days to 12 months postpartum.
12. A method for treating a disorder treatable with solriamfetol in a human subject producing breast milk for feeding an infant, comprising:
administering solriamfetol orally at a once-daily dose of about 150 to the subject; and
reducing exposure of the infant to solriamfetol and/or decreasing the potential for adverse events in the infant fed breast milk from the subject, comprising feeding the infant breast milk obtained from the subject at least about 5 hours after administering the solriamfetol to the subject,
wherein the daily infant dose of solriamfetol is reduced to about 0.3 mg or lower.
13. The method of claim 12 , wherein the disorder treatable with solriamfetol is narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, cognitive impairment, attention deficit/hyperactivity disorder, depression, or binge eating disorder.
14. The method of claim 12 , wherein the infant does not experience agitation, insomnia, anorexia, or reduced weight gain due to solriamfetol exposure.
15. The method of claim 12 , wherein the adverse events are one or more of agitation, insomnia, anorexia, or reduced weight gain.
16. The method of claim 12 , wherein the subject is from 1 day to 24 months postpartum.
17. The method of claim 16 , wherein the subject is from 10 days to 12 months postpartum.
18. The method of claim 12 , wherein the subject is a woman between the ages of 18 and 45 years.
19. The method of claim 5 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, major depression, shift work disorder, or Parkinson's disease.
20. The method of claim 8 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, major depression, shift work disorder, or Parkinson's disease.
21. The method of claim 13 , where the excessive daytime sleepiness is due to narcolepsy, obstructive sleep apnea, major depression, shift work disorder, or Parkinson's disease.